Above all, we make a difference.
Home > Breast Cancer Information > Screening & Early Detection > Screening & Early Detection References

Screening & Early Detection References

  1. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in SEER age-adjusted mortality rates, 1975-2022, by sex, all races, all ages. Accessed on April 18, 2024. https://seer.cancer.gov/explorer/, 2024.
  2. American Cancer Society. American Cancer Society recommendations for the early detection of breast cancer. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html, 2023.
  3. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer screening and diagnosis, Version 2.2024. http://www.nccn.org, 2024.
  4. Nicholson WK, Silverstein M, Wong JB, et al. for the US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 329(23):2057-2067, 2024.
  5. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 258(1):98-105, 2011.
  6. de Gelder R, Draisma G, Heijnsdijk EA, de Koning HJ. Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. Br J Cancer. 104(7):1214-20, 2011.
  7. Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med. 164(4):205-14, 2016.
  8. Neal CH, Helvie MA. Overdiagnosis and risks of breast cancer screening. Radiol Clin North Am. 59(1):19-27, 2021.
  9. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 6:CD001877, 2013.
  10. Patel BK, Carnahan MB, Northfelt D, et al. Prospective study of supplemental screening with contrast-enhanced mammography in women with elevated risk of breast cancer: results of the prevalence round. J Clin Oncol. 42(32):3826-3836, 2024.
  11. U.S. Centers for Medicare & Medicaid Services. Preventive care benefits for women. https://www.healthcare.gov/preventive-care-women/, 2022.
  12. Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 164(4):268-78, 2016.
  13. Lehman CD, Arao RF, Sprague BL, et al. National performance benchmarks for modern screening digital mammography: update from the Breast Cancer Surveillance Consortium. Radiology. 283(1): 49–58, 2017.
  14. Alabousi M, Wadera A, Kashif Al-Ghita M, et al. Performance of digital breast tomosynthesis, synthetic mammography, and digital mammography in breast cancer screening: a systematic review and meta-analysis. J Natl Cancer Inst. 113(6):680-690, 2021.
  15. Richman IB, Long JB, Hoag JR, et al. Comparative effectiveness of digital breast tomosynthesis for breast cancer screening among women 40-64 years old. J Natl Cancer Inst. 113(11):1515-1522, 2021.
  16. Lee CS, Goldman L, Grimm LJ, et al. Screening mammographic performance by race and age in the National Mammography Database: 29,479,665 screening mammograms from 13,181,241 women. Breast Cancer Res Treat. 203(3):599-612, 2024.
  17. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 164(4):256-67, 2016.
  18. Ho TH, Bissell MCS, Kerlikowske K, et al. Cumulative probability of false-positive results after 10 years of screening with digital breast tomosynthesis vs digital mammography. JAMA Netw Open. 5(3):e222440, 2022.
  19. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.
  20. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 103(15):1179-89, 2011.
  21. Gierach GL, Ichikawa L, Kerlikowske K, et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 104(16):1218-27, 2012.
  22. van der Waal D, Verbeek ALM, Broeders MJM. Breast density and breast cancer-specific survival by detection mode. BMC Cancer. 18(1):386, 2018.
  23. Heindl F, Fasching PA, Hein A, et al. Mammographic density and prognosis in primary breast cancer patients. Breast. 59:51-57, 2021.
  24. Canadian Cancer Society. Breast calcifications. https://cancer.ca/en/cancer-information/cancer-types/breast/what-is-breast-cancer/breast-calcifications, 2024.
  25. D’Orsi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA. American College of Radiology, 2013.
  26. American Cancer Society. Understanding your mammogram report. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/understanding-your-mammogram-report.html, 2022.
  27. Qaseem A, Lin JS, Mustafa RA, et al. for the Clinical Guidelines Committee of the American College of Physicians. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann Intern Med. 170(8):547-560, 2019.
  28. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 164(4):244-55, 2016.
  29. American Geriatrics Society. Choosing wisely and the American Geriatrics Society. https://www.americangeriatrics.org/sites/default/files/inline-files/AGS%20Choosing%20Wisely%20Poster.pdf, 2015.
  30. Lee CI, Abraham L, Miglioretti DL, et al. for the Breast Cancer Surveillance Consortium. National performance benchmarks for screening digital breast tomosynthesis: update from the Breast Cancer Surveillance Consortium. Radiology. 307(4):e222499, 2023.
  31. National Cancer Institute. Breast cancer screening (PDQ®)-health professional version. https://www.cancer.gov/types/breast/hp/breast-screening-pdq, 2024.
  32. Breast Cancer Surveillance Consortium. BCSC mammography data. https://www.bcsc-research.org/index.php/statistics/mammography_data, Accessed on December 31, 2024.
  33. Miglioretti DL, Abraham L, Sprague BL, et al. Association between false-positive results and return to screening mammography in the Breast Cancer Surveillance Consortium cohort. Ann Intern Med. 177(10):1297-1307, 2024.
  34. Bolejko A, Hagell P, Wann-Hansson C, Zackrisson S. Prevalence, long-term development, and predictors of psychosocial consequences of false-positive mammography among women attending population-based screening. Cancer Epidemiol Biomarkers Prev. 24(9):1388-97, 2015.
  35. Gram EG, Siersma V, Brodersen JB. Long-term psychosocial consequences of false-positive screening mammography: a cohort study with follow-up of 12-14 years in Denmark. BMJ Open. 13(4):e072188, 2023.
  36. Rossouw JE, Anderson GL, Prentice RL, et al. for the Women’s Health Initiative (WHI) Investigators Writing Group. Risk and benefits of estrogen plus progestin in health postmenopausal women: Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 288(3):321-33, 2002.
  37. U.S. Food and Drug Administration. Menopause & hormones: common questions. https://www.fda.gov/media/130242/download, 2019.
  38. Chlebowski RT, Hendrix SL, Langer RD, et al. for the Women’s Health Initiative Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA. 289(24):3243-53, 2003.
  39. McTiernan A, Martin CF, Peck JD, et al. for the Women’s Health Initiative Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women’s health initiative randomized trial. J Natl Cancer Inst. 97(18):1366-76, 2005.
  40. Stefanick ML, Anderson GL, Margolis KL, et al. for the Women’s Health Initiative Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 295(14):1647-57, 2006.
  41. McTiernan A, Chlebowski RT, Martin C, et al. for the Women’s Health Initiative Investigators. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol. 27(36):6135-43, 2009.
  42. Chlebowski RT, Anderson G, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol. 28(16):2690-7, 2010.
  43. Johansson A, Christakou AE, Iftimi A, et al. Characterization of benign breast diseases and association with age, hormonal factors, and family history of breast cancer among women in Sweden. JAMA Netw Open. 4(6):e2114716, 2021.
  44. Rawashdeh MA, Lee WB, Bourne RM, et al. Markers of good performance in mammography depend on number of annual readings. Radiology. 269(1):61-7, 2013.
  45. Théberge I, Chang SL, Vandal N, et al. Radiologist interpretive volume and breast cancer screening accuracy in a Canadian organized screening program. J Natl Cancer Inst. 106(3):djt461, 2014.
  46. Giess CS, Wang A, Ip IK, Lacson R, Pourjabbar S, Khorasani R. Patient, radiologist, and examination characteristics affecting screening mammography recall rates in a large academic practice. J Am Coll Radiol. 16(4 Pt A):411-418, 2019.
  47. Walker MJ, Hartman K, Majpruz V, et al. The impact of radiologist screening mammogram reading volume on performance in the Ontario Breast Screening Program. Can Assoc Radiol J. 73(2):362-370, 2022.
  48. Lee CS, Bhargavan-Chatfield M, Burnside ES, Nagy P, Sickles EA. The National Mammography Database: preliminary data. AJR Am J Roentgenol. 206(4):883-90, 2016.
  49. Durand MA, Friedewald SM, Plecha DM, et al. False-negative rates of breast cancer screening with and without digital breast tomosynthesis. Radiology. 298(2):296-305, 2021.
  50. Hayward JH, Linden OE, Lewin AA, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® monitoring response to neoadjuvant systemic therapy for breast cancer: 2022 update. J Am Coll Radiol. 20(5S):S125-S145, 2023.
  51. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer- SEER 5-year age-adjusted incidence rates, 20017-2021 by age, female, all races/ethnicities, all stages. Accessed on January 2, 2025. https://seer.cancer.gov/explorer/, 2025.
  52. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 348:g366, 2014.
  53. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med. 166(5):313-323, 2017.
  54. Autier P, Boniol M, Koechlin A, Pizot C, Boniol M. Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. BMJ. 359:j5224, 2017.
  55. Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hübner J. Breast cancer incidence and mortality before and after implementation of the German Mammography Screening Program. Int J Cancer. 147(3):709-718, 2020.
  56. Neal CH, Helvie MA. Overdiagnosis and risks of breast cancer screening. Radiol Clin North Am. 59(1):19-27, 2021.
  57. Ryser MD, Lange J, Inoue LYT, et al. Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort. Ann Intern Med. 175(4):471-478, 2022.
  58. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 314(15):1615-34, 2015.
  59. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 103(9):1778-1784, 2005.
  60. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 97(2):135-144, 2006.
  61. Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 28(5):662-669, 2015.
  62. American Cancer Society. Getting called back after a mammogram. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/mammograms/getting-called-back-after-a-mammogram.html, 2022.
  63. American Cancer Society. Breast cancer signs and symptoms. https://www.cancer.org/cancer/breast-cancer/about/breast-cancer-signs-and-symptoms.html, 2022.
  64. Centers for Disease Control and Prevention. Symptoms of breast cancer. https://www.cdc.gov/breast-cancer/symptoms/, 2024.
  65. Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (review). Cochrane Database Syst Rev. Issue 3: CD003373, 2008.
  66. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: breast, ovarian, pancreatic and prostate. Version 2.2025. http://www.nccn.org, 2025.
  67. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer, Version 6.2024. http://www.nccn.org, 2024.
  68. Saslow D, Boetes C, Burke W, et al. for the American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 57(2):75-89, 2007.
  69. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer. 118(8):2021-30, 2012.
  70. Chiarelli AM, Prummel MV, Muradali D, et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario High Risk Breast Screening Program. J Clin Oncol. 32(21):2224-30, 2014.
  71. Phi XA, Saadatmand S, De Bock GH, et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer. 114(6):631-7, 2016.
  72. Lubinski J, Kotsopoulos J, Moller P, et al. for the Hereditary Breast Cancer Clinical Study Group. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 10(4):493-499, 2024.
  73. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 365:l1652, 2019.
  74. Corso G, Gandini S, D’Ecclesiis O, et al. Risk and incidence of breast cancer in transgender individuals: a systematic review and meta-analysis. Eur J Cancer Prev. 32(3):207-214, 2023.
  75. Brown A, Lourenco AP, Niell BL, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® transgender breast cancer screening. J Am Coll Radiol. 18(11S):S502-S515, 2021.
  76. American College of Radiology. ACR Appropriateness Criteria: Transgender breast cancer screening. https://acsearch.acr.org/docs/3155692/Narrative/, 2021.
  77. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:1633-7, 2001.
  78. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. (11):CD002748, 2010.
  79. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 374(5):454-68, 2016.
  80. Mallio CA, Rovira A, Parizel PM, Quattrocchi CC. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology. 62(8):925-934, 2020.
  81. Mota BS, Nunes Reis YN, de Barros N, et al. Effects of preoperative magnetic resonance image on survival rates and surgical planning in breast cancer conservative surgery: randomized controlled trial (BREAST-MRI trial). Breast Cancer Res Treat. 198(3):447-461, 2023.
  82. Kerlikowske K, Zhu W, Su YR, et al. Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density. J Natl Cancer Inst. 116(2):249-257, 2024.
  83. Stout NK, Miglioretti DL, Su YR, et al. Breast cancer screening using mammography, digital breast tomosynthesis, and magnetic resonance imaging by breast density. JAMA Intern Med. 184(10):1222-1231, 2024.
  84. Mattar A, Antonini M, Amorim A, et al. PROMRIINE (PRe-operatory Magnetic Resonance Imaging is INEffective) study: a systematic review and meta-analysis of the impact of magnetic resonance imaging on surgical decisions and clinical outcomes in women with breast cancer. Ann Surg Oncol. 31(12):8021-8029, 2024.
  85. Berg WA, Zhang Z, Lehrer D, et al. for the ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 307(13):1394-404, 2012.
  86. Cho N, Han W, Han BK, et al. Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol. 3(11):1495-1502, 2017.
  87. Buist DSM, Abraham L, Lee CI, et al. for the Breast Cancer Surveillance Consortium. Breast biopsy intensity and findings following breast cancer screening in women with and without a personal history of breast cancer. JAMA Intern Med. 178(4):458-468, 2018.
  88. Wernli KJ, Ichikawa L, Kerlikowske K, et al. Surveillance breast MRI and mammography: comparison in women with a personal history of breast cancer. Radiology. 292:311–318, 2019.
  89. Haas CB, Nekhlyudov L, Lee JM, et al. Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. Breast Cancer Res Treat. 181:255-68, 2020.
  90. McDonald ES, Scheel JR, Lewin AA, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer. J Am Coll Radiol. 21(6S):S168-S202 2024.
  91. Bakker MF, de Lange SV, Pijnappel RM, et al. for the DENSE Trial Study Group. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med. 381(22):2091-2102, 2019.
  92. Geuzinge HA, Bakker MF, Heijnsdijk EAM, et al. for the DENSE trial study group. Cost-effectiveness of magnetic resonance imaging screening for women with extremely dense breast tissue. J Natl Cancer Inst. 113(11):1476-1483, 2021.
  93. Hussein H, Abbas E, Keshavarzi S, et al. Supplemental breast cancer screening in women with dense breasts and negative mammography: a systematic review and meta-analysis. Radiology. 306(3):e221785, 2023.
  94. Glechner A, Wagner G, Mitus JW, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev. 3(3):CD009632, 2023.
  95. Mizzi D, Allely C, Zarb F, et al. Examining the effectiveness of supplementary imaging modalities for breast cancer screening in women with dense breasts: A systematic review and meta-analysis. Eur J Radiol. 154:11046, 2022.
  96. Giger ML, Inciardi MF, Edwards A, et al. Automated breast ultrasound in breast cancer screening of women with dense breasts: reader study of mammography-negative and mammography-positive cancers. AJR Am J Roentgenol. 206(6):1341-50, 2016.
  97. Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. J Clin Oncol. 34(16):1882-8, 2016.
  98. Yuan WH, Hsu HC, Chen YY, Wu CH. Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis. Br J Cancer. 123(4):673-688, 2020.
  99. Yi A, Jang MJ, Yim D, Kwon BR, Shin SU, Chang JM. Addition of screening breast US to digital mammography and digital breast tomosynthesis for breast cancer screening in women at average risk. Radiology. 298(3):568-575, 2021.
  100. Berg WA, Zuley ML, Chang TS, et al. Prospective multicenter diagnostic performance of technologist-performed screening breast ultrasound after tomosynthesis in women with dense breasts (the DBTUST). J Clin Oncol. 41(13):2403-2415, 2023.
  101. Lång K, Josefsson V, Larsson AM, et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol. 24(8):936-944, 2023.
  102. Yoon JH, Strand F, Baltzer PAT, et al. Standalone AI for breast cancer detection at screening digital mammography and digital breast tomosynthesis: a systematic review and meta-analysis. Radiology. 307(5):e222639, 2023.
  103. Lauritzen AD, Lillholm M, Lynge E, Nielsen M, Karssemeijer N, Vejborg I. Early indicators of the impact of using AI in mammography screening for breast cancer. Radiology. 311(3):e232479, 2024.
  104. Elías-Cabot E, Romero-Martín S, Raya-Povedano JL, Brehl AK, Álvarez-Benito M. Impact of real-life use of artificial intelligence as support for human reading in a population-based breast cancer screening program with mammography and tomosynthesis. Eur Radiol. 34(6):3958-3966, 2024.
  105. Berg WA, Rafferty EA, Friedewald SM, Hruska CB, Rahbar H. Screening algorithms in dense breasts: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 216(2):275-294, 2021.
  106. Berg WA, Berg JM, Bandos AI, et al. Addition of contrast-enhanced mammography to tomosynthesis for breast cancer detection in women with a personal history of breast cancer: prospective TOCEM trial interim analysis. Radiology. 311(1):e231991, 2024.
  107. Nissan N, Comstock CE, Sevilimedu V, et al. Diagnostic accuracy of screening contrast-enhanced mammography for women with extremely dense breasts at increased risk of breast cancer. Radiology. 313(1):e232580, 2024.
  108. Sogani J, Morris E, Kaplan J, et al. Comparison of background parenchymal enhancement at contrast-enhanced spectral mammography and breast MR imaging. Radiology. 282:63–73, 2017.
  109. Covington MF, Pizzitola VJ, Lorans R, et al. The future of contrast-enhanced mammography. AJR Am J Roentgenol. 210(2):292-300, 2018.
  110. MacCallum C, Elder K, Nickson C, et al. Contrast-enhanced mammography in local staging of screen-detected breast cancer. Ann Surg Oncol. 31(10):6820-6830, 2024.
  111. Shermis RB, Wilson KD, Doyle MT, et al. Supplemental breast cancer screening with molecular breast imaging for women with dense breast tissue. AJR Am J Roentgenol. 207(2):450-7, 2016.
  112. Hruska CB. Molecular breast imaging for screening in dense breasts: state of the art and future directions. AJR Am J Roentgenol. 208(2):275-283, 2017.
  113. Comstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA. 323(8):746-756, 2020.
  114. Weinstein SP, Korhonen K, Cirelli C, et al. Abbreviated breast magnetic resonance imaging for supplemental screening of women with dense breasts and average risk. J Clin Oncol. 38(33):3874-3882, 2020.
  115. Geach R, Jones LI, Harding SA, et al. for the FAST MRI Study Group. The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis. Clin Radiol. 76(2):154, 2021.
  116. Kwon MR, Choi JS, Won H, et al. Breast cancer screening with abbreviated breast MRI: 3-year outcome analysis. Radiology. 299(1):73-83, 2021.
  117. Kim SY, Cho N, Hong H, et al. Abbreviated screening MRI for women with a history of breast cancer: comparison with full-protocol breast MRI. Radiology. 305(1):36-45, 2022.
  118. Lee CI and Elmore JC. Chapter 11. Breast Cancer Screening, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  119. Mainiero MB, Lourenco A, Mahoney MC, et al. ACR Appropriateness Criteria breast cancer screening. J Am Coll Radiol. 13(11S):R45-R49, 2016.
  120. U.S. Food and Drug Administration (FDA). Breast cancer screening: thermogram no substitute for mammogram. https://www.fda.gov/consumers/consumer-updates/breast-cancer-screening-thermogram-no-substitute-mammogram, 2023.
  121. Jourquin J, Reffey SB, Jernigan C, et al. Susan G. Komen Big Data for Breast Cancer initiative: how patient advocacy organizations can facilitate using big data to improve patient outcomes. JCO Precis Oncol. 3:PO.19.00184, 2019.
  122. Yala A, Lehman C, Schuster T, Portnoi T, Barzilay R. A deep learning mammography-based model for improved breast cancer risk prediction. Radiology. 292(1):60-66, 2019.
  123. Yala A, Schuster T, Miles R, Barzilay R, Lehman C. A deep learning model to triage screening mammograms: a simulation study. Radiology. 293(1):38-46, 2019.
  124. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures, 2023-2024. Atlanta, GA: American Cancer Society, 2023.
  125. American Cancer Society. Breast Cancer Facts and Figures 2024-2025. Atlanta, GA: American Cancer Society, 2024.
  126. Ramachandran A, Snyder FR, Katz ML, et al. for the Patient Navigation Research Program Investigators. Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: data from the Patient Navigation Research Program. Cancer. 121(22):4016-24, 2015.
  127. Shoemaker ML, White MC. Breast and cervical cancer screening among Hispanic subgroups in the USA: estimates from the National Health Interview Survey 2008, 2010, and 2013. Cancer Causes Control. 27(3):453-7, 2016.
  128. Shoemaker ML, White MC. Breast and cervical cancer screening among Asian subgroups in the USA: estimates from the National Health Interview Survey, 2008, 2010, and 2013. Cancer Causes Control. 27(6):825-9, 2016.
  129. White A, Thompson TD, White MC, et al. Cancer screening test use – United States, 2015. MMWR Morb Mortal Wkly Rep. 66(8):201-206, 2017.
  130. Henderson LM, O’Meara ES, Haas JS, et al. The role of social determinants of health in self-reported access to health care among women undergoing screening mammography. J Womens Health (Larchmt). 29(11):1437-1446, 2020.
  131. Kurani SS, McCoy RG, Lampman MA, et al. Association of neighborhood measures of social determinants of health with breast, cervical, and colorectal cancer screening rates in the US Midwest. JAMA Netw Open. 3(3):e200618, 2020.
  132. Hernandez AE, Borowsky PA, Lubarsky M, et al. Associations between perceived discrimination, screening mammography, and breast cancer stage at diagnosis: a prospective cohort analysis. Ann Surg Oncol. 31(12):8012-8020, 2024.
  133. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – 5-year age-adjusted incidence rates, 2017-2021, by race/ethnicity, female, all ages, all stages. Accessed on April 22, 2024. https://seer.cancer.gov/explorer/, 2024.
  134. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – U.S. 5-year age-adjusted mortality rates, 2018-2022, by race/ethnicity, female, all ages. Accessed on April 22, 2024. https://seer.cancer.gov/explorer/, 2024.
  135. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in SEER age-adjusted incidence rates, 1975-2021, by race/ethnicity, observed SEER incidence rate, female, all ages. Accessed on April 22, 2024. https://seer.cancer.gov/explorer/, 2024.
  136. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in U.S. age-adjusted mortality rates, 1975-2022, by race/ethnicity, female, all ages. Accessed on April 22, 2024. https://seer.cancer.gov/explorer/, 2024.
  137. Miller-Kleinhenz JM, Collin LJ, Seidel R, et al. Racial disparities in diagnostic delay among women with breast cancer. J Am Coll Radiol. 18(10):1384-1393, 2021.
  138. Lawson MB, Bissell MCS, Miglioretti DL, et al. Multilevel factors associated with time to biopsy after abnormal screening mammography results by race and ethnicity. JAMA Oncol. 8(8):1115-1126, 2022.
  139. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313(2):165-73, 2015.
  140. American Cancer Society. Cancer Facts and Figures for African American/Black People 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  141. American Cancer Society. Cancer Facts and Figures 2025. Atlanta, GA: American Cancer Society, 2025.
  142. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer- Breast cancer median age at diagnosis 2017-2021, by race/ethnicity, female. Accessed on April 23, 2024. https://seer.cancer.gov/explorer/, 2024.
  143. American Cancer Society. Cancer Facts and Figures for Hispanics/Latinos, 2024-2026. Atlanta, GA: American Cancer Society, 2024.
  144. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 75(1):10-45, 2025.
  145. Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS. Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups. Cancer. 123(18):3468-3475, 2017.
  146. Towne SD Jr, Smith ML, Ory MG. Geographic variations in access and utilization of cancer screening services: examining disparities among American Indian and Alaska Native Elders. Int J Health Geogr. 13:18, 2014.
  147. American Cancer Society. Cancer Facts and Figures 2022. Atlanta, GA: American Cancer Society, 2022.
  148. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer – SEER 5-year age-adjusted incidence rates, 2017-2021, by race/ethnicity, female, all ages, localized. Accessed on May 6, 2024. https://seer.cancer.gov/explorer/, 2024.
  149. Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in cancer incidence and trends among American Indians and Alaska Natives in the United States, 2010-2015. Cancer Epidemiol Biomarkers Prev. 28(10):1604-1611, 2019.
  150. Gopalani SV, Janitz AE, Martinez SA, Gutman P, Khan S, Campbell JE. Trends in cancer incidence among American Indians and Alaska Natives and non-Hispanic Whites in the United States, 1999-2015. Epidemiology. 31(2):205-213, 2020.
  151. Agénor M, Pérez AE, Tabaac AR, et al. Sexual orientation identity disparities in mammography among white, Black, and Latina U.S. women. LGBT Health. 7(6):312-320, 2020.
  152. Williams AD, Bleicher RJ, Ciocca RM. Breast cancer risk, screening, and prevalence among sexual minority women: an analysis of the National Health Interview Survey. LGBT Health. 7(2):109-118, 2020.
  153. Lee M, Jenkins WD, Boakye EA. Cancer screening utilization by residence and sexual orientation. Cancer Causes Control. 31(10):951-964, 2020.
  154. Horner-Johnson W, Dobbertin K, Andresen EM, Iezzoni LI. Breast and cervical cancer screening disparities associated with disability severity. Womens Health Issues. 24(1):e147-53, 2014.
  155. Centers for Disease Control and Prevention. Women with disabilities and breast cancer screening. https://www.cdc.gov/disability-and-health/conditions/breast-cancer-screening.html, 2024.
  156. Keegan G, Rizzo JR, Joseph KA. Disparities in breast cancer among patients with disabilities: care gaps, accessibility, and best practices. J Natl Cancer Inst. 115(10):1139-1144, 2023.
  157. Fazeli S, Narayan A, Mango VL, Wahab R, Mehta TS, Ojeda-Fournier H. Access to breast cancer screening: disparities and determinants – AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2024 Nov 27 [Online ahead of print].
  158. Ramjan L, Cotton A, Algoso M, Peters K. Barriers to breast and cervical cancer screening for women with physical disability: a review. Women Health. 56(2):141-56, 2016.
  159. Centers for Disease Control and Prevention. Disability and health information for women. https://www.cdc.gov/disability-and-health/about/information-for-women.html, 2024.
  160. Khushalani JS, Ekwueme DU, Richards TB, et al. Utilization and cost of mammography screening among commercially insured women 50 to 64 years of age in the United States, 2012-2016. J Womens Health (Larchmt). 29(3):327-337, 2020.
  161. Cooper GS, Kou TD, Dor A, Koroukian SM, Schluchter MD. Cancer preventive services, socioeconomic status, and the Affordable Care Act. Cancer. 123(9):1585-1589, 2017.
  162. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol. 32(5):392-401, 2014.
  163. Sardanelli F, Trimboli RM, Houssami N, et al. Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysis (MIPA). Eur Radiol. 32(3):1611-1623, 2022.
  164. Eisemann N, Bunk S, Mukama T, et al. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nat Med. 2025 Jan 7 [Online ahead of print].
  165. Radiological Society of North America (RSNA) and the American College of Radiology (ACR), Palpable breast masses. https://www.radiologyinfo.org/en/info/acs-palpable-breast-masses, 2024.
  166. Sabel MS. Clinical manifestations, differential diagnosis, and clinical evaluation of a palpable breast mass. In: UpToDate. Chapgar AB and Chen W(eds.). Waltham, MA: UpToDate, 2025.

Updated 03/17/25

This content is regularly reviewed by an expert panel including researchers, practicing clinicians and patient advocates.

 

TOOLS & RESOURCES

PDF

Fact Sheet

Support After a Breast Cancer Diagnosis

PDF

Fact Sheet

What is Breast Cancer?